Zacks: Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) to Announce -$0.17 EPS

Equities research analysts expect that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will post ($0.17) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Halozyme Therapeutics’ earnings, with estimates ranging from ($0.22) to ($0.13). Halozyme Therapeutics posted earnings per share of ($0.16) in the same quarter last year, which would suggest a negative year-over-year growth rate of 6.3%. The company is scheduled to announce its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that Halozyme Therapeutics will report full year earnings of ($0.43) per share for the current fiscal year, with EPS estimates ranging from ($0.48) to ($0.39). For the next year, analysts expect that the firm will post earnings of ($0.47) per share, with EPS estimates ranging from ($0.87) to ($0.23). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Halozyme Therapeutics.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, May 7th. The biopharmaceutical company reported $0.01 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.01. The business had revenue of $56.95 million for the quarter, compared to analyst estimates of $67.80 million. Halozyme Therapeutics had a negative net margin of 28.70% and a negative return on equity of 20.36%. Halozyme Therapeutics’s revenue was up 84.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.19) EPS.

A number of analysts recently weighed in on HALO shares. JMP Securities reaffirmed a “buy” rating and set a $21.00 target price on shares of Halozyme Therapeutics in a report on Wednesday, February 27th. Zacks Investment Research lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, April 25th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $24.00 target price on shares of Halozyme Therapeutics in a report on Monday, February 4th. TheStreet lowered shares of Halozyme Therapeutics from a “c” rating to a “d” rating in a report on Tuesday, March 5th. Finally, BidaskClub raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 15th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $20.40.

Halozyme Therapeutics stock opened at $15.83 on Wednesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.71 and a current ratio of 2.95. The company has a market cap of $2.26 billion, a P/E ratio of -28.27 and a beta of 1.79. Halozyme Therapeutics has a 1-year low of $13.24 and a 1-year high of $19.94.

A number of institutional investors have recently bought and sold shares of HALO. Bank of Montreal Can increased its holdings in shares of Halozyme Therapeutics by 80.4% in the 4th quarter. Bank of Montreal Can now owns 2,011 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 896 shares during the last quarter. Sageworth Trust Co increased its holdings in shares of Halozyme Therapeutics by 4,200.0% in the 1st quarter. Sageworth Trust Co now owns 2,150 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 2,100 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth $140,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Halozyme Therapeutics by 33.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,791 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 2,430 shares during the last quarter. Finally, Paloma Partners Management Co bought a new position in shares of Halozyme Therapeutics in the 4th quarter worth $150,000. 83.33% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

There is no company description available for Halozyme Therapeutics Inc

Featured Article: What is range trading?

Get a free copy of the Zacks research report on Halozyme Therapeutics (HALO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.